AGIOS PHARMACEUTICALS, INC. 10-Q filing
Filed 2026-04-29 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001439222-26-000073
- Form type
- 10-Q
- CIK
- 0001439222
- Primary document
- https://www.sec.gov/Archives/edgar/data/1439222/000143922226000073/agio-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for AGIOS PHARMACEUTICALS, INC..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $20.7M | - | - |
| Cost Of Revenue | $1.3M | - | - |
| Operating Income | $-110.0M | - | - |
| Net Income | $-99.1M | - | - |
| Eps Basic | -1.69 | - | - |
| Eps Diluted | -1.69 | - | - |
| Cash And Equivalents | $113.6M | - | - |
| Total Assets | $1.2B | - | - |
| Total Liabilities | $75.9M | - | - |
| Shareholders Equity | $1.1B | - | - |
| Operating Cash Flow | $-118.9M | - | - |
| Capital Expenditures | $769,000 | - | - |